Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary

Background: The effects of halobetasol propionate (HBP) lotion 0.05% on the hypothalamic-pituitary-adrenal (HPA) axis have not been previously evaluated in adolescents. Objective: To examine the effect of HBP on HPA axis suppression in patients aged <17 years with plaque psoriasis. Methods: In th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vivian Laquer, MD, Andrea Nguyen, PA-C, MS, Nicholas Squittieri, MD, Tien Nguyen, MD
Formato: article
Lenguaje:EN
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://doaj.org/article/9b2fd133847845d3a895f520e3ec634f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9b2fd133847845d3a895f520e3ec634f
record_format dspace
spelling oai:doaj.org-article:9b2fd133847845d3a895f520e3ec634f2021-11-26T04:40:53ZHalobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary2666-328710.1016/j.jdin.2021.10.003https://doaj.org/article/9b2fd133847845d3a895f520e3ec634f2022-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666328721000821https://doaj.org/toc/2666-3287Background: The effects of halobetasol propionate (HBP) lotion 0.05% on the hypothalamic-pituitary-adrenal (HPA) axis have not been previously evaluated in adolescents. Objective: To examine the effect of HBP on HPA axis suppression in patients aged <17 years with plaque psoriasis. Methods: In this phase 4, open-label, multicenter study, patients aged 12 to 16 years 11 months with stable plaque psoriasis covering ≥10% of their body surface area were enrolled. The patients applied an HBP lotion twice daily for up to 2 weeks. The cosyntropin stimulation test was used to determine cortisol levels at the time of screening and at the end of the study to evaluate HPA axis response. The additional endpoints included adverse events, disease severity (measured using Investigator Global Assessment score), and percent body surface area affected. Results: Sixteen patients were enrolled and included in the safety population; 14 were included in the evaluable population. One patient exhibited an abnormal HPA axis response (16.2 μg/dL) at the end of the study; the response returned to normal at the 6-month follow-up visit. By the end of the study, the Investigator Global Assessment score improved by ≥1 point in most patients; moreover, the percent body surface area affected decreased from 11.5% to 2.8%. One mild adverse event was possibly related to the HBP lotion; however, it resolved and did not cause study discontinuation. Limitations: Small sample size. Conclusion: The HBP lotion 0.05% appeared efficacious and well tolerated in patients as young as 12 years old.Vivian Laquer, MDAndrea Nguyen, PA-C, MSNicholas Squittieri, MDTien Nguyen, MDElsevierarticleadolescentadrenal suppressioncorticosteroidshalobetasol propionatepharmacologypsoriasisDermatologyRL1-803ENJAAD International, Vol 6, Iss , Pp 13-19 (2022)
institution DOAJ
collection DOAJ
language EN
topic adolescent
adrenal suppression
corticosteroids
halobetasol propionate
pharmacology
psoriasis
Dermatology
RL1-803
spellingShingle adolescent
adrenal suppression
corticosteroids
halobetasol propionate
pharmacology
psoriasis
Dermatology
RL1-803
Vivian Laquer, MD
Andrea Nguyen, PA-C, MS
Nicholas Squittieri, MD
Tien Nguyen, MD
Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
description Background: The effects of halobetasol propionate (HBP) lotion 0.05% on the hypothalamic-pituitary-adrenal (HPA) axis have not been previously evaluated in adolescents. Objective: To examine the effect of HBP on HPA axis suppression in patients aged <17 years with plaque psoriasis. Methods: In this phase 4, open-label, multicenter study, patients aged 12 to 16 years 11 months with stable plaque psoriasis covering ≥10% of their body surface area were enrolled. The patients applied an HBP lotion twice daily for up to 2 weeks. The cosyntropin stimulation test was used to determine cortisol levels at the time of screening and at the end of the study to evaluate HPA axis response. The additional endpoints included adverse events, disease severity (measured using Investigator Global Assessment score), and percent body surface area affected. Results: Sixteen patients were enrolled and included in the safety population; 14 were included in the evaluable population. One patient exhibited an abnormal HPA axis response (16.2 μg/dL) at the end of the study; the response returned to normal at the 6-month follow-up visit. By the end of the study, the Investigator Global Assessment score improved by ≥1 point in most patients; moreover, the percent body surface area affected decreased from 11.5% to 2.8%. One mild adverse event was possibly related to the HBP lotion; however, it resolved and did not cause study discontinuation. Limitations: Small sample size. Conclusion: The HBP lotion 0.05% appeared efficacious and well tolerated in patients as young as 12 years old.
format article
author Vivian Laquer, MD
Andrea Nguyen, PA-C, MS
Nicholas Squittieri, MD
Tien Nguyen, MD
author_facet Vivian Laquer, MD
Andrea Nguyen, PA-C, MS
Nicholas Squittieri, MD
Tien Nguyen, MD
author_sort Vivian Laquer, MD
title Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
title_short Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
title_full Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
title_fullStr Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
title_full_unstemmed Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
title_sort halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: results of an open-label study evaluating adrenal suppression potentialcapsule summary
publisher Elsevier
publishDate 2022
url https://doaj.org/article/9b2fd133847845d3a895f520e3ec634f
work_keys_str_mv AT vivianlaquermd halobetasolpropionatelotion005inpatients12to16years11monthsofagewithplaquepsoriasisresultsofanopenlabelstudyevaluatingadrenalsuppressionpotentialcapsulesummary
AT andreanguyenpacms halobetasolpropionatelotion005inpatients12to16years11monthsofagewithplaquepsoriasisresultsofanopenlabelstudyevaluatingadrenalsuppressionpotentialcapsulesummary
AT nicholassquittierimd halobetasolpropionatelotion005inpatients12to16years11monthsofagewithplaquepsoriasisresultsofanopenlabelstudyevaluatingadrenalsuppressionpotentialcapsulesummary
AT tiennguyenmd halobetasolpropionatelotion005inpatients12to16years11monthsofagewithplaquepsoriasisresultsofanopenlabelstudyevaluatingadrenalsuppressionpotentialcapsulesummary
_version_ 1718409795680075776